HIV resistance mutations are genetic changes that can reduce the effectiveness of antiretroviral medications. These mutations may develop when the virus continues replicating during treatment, particularly when medication levels are insufficient or treatment is interrupted. Understanding resistance patterns across drug classes helps explain treatment failure, resistance testing, and the importance of selecting effective antiretroviral combinations.
Different antiretroviral drug classes target specific stages of the HIV life cycle. Mutations affecting one drug class may not necessarily influence another, although some mutations can produce cross-resistance between medications with similar mechanisms of action. Understanding these differences helps healthcare professionals interpret resistance testing and make informed treatment decisions.
HIV resistance mutations develop when genetic changes allow certain viral strains to reproduce despite exposure to antiretroviral medications. These mutations can occur naturally or emerge under selective pressure during treatment. Their effects depend on the specific mutation, the medication involved, and the combination of other resistance-related changes.
The major antiretroviral drug classes have different resistance patterns.
Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Mutations such as M184V can reduce susceptibility to lamivudine and emtricitabine. Other mutations, including K65R and thymidine analogue mutations, can affect susceptibility to multiple NRTIs.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Mutations such as K103N, Y181C, and G190A may reduce the effectiveness of medications including efavirenz, nevirapine, and other drugs within this class.
Protease Inhibitors (PIs): Mutations in the HIV protease gene can alter the enzyme targeted by these medications. Changes such as D30N, V82A, and I84V may contribute to resistance against particular protease inhibitors.
Integrase Strand Transfer Inhibitors (INSTIs): Mutations such as G140S, Q148H, and N155H can affect integrase inhibitor susceptibility. Their clinical significance depends on combinations of mutations and the specific medication.
Fusion and Entry Inhibitors: Resistance can develop through changes in viral envelope proteins. For example, mutations in the gp41 region may influence susceptibility to enfuvirtide, while changes involving the CCR5 coreceptor pathway can affect maraviroc activity.
These mutation patterns demonstrate why resistance interpretation requires more than identifying a single genetic change.
Cross-resistance occurs when a mutation selected by one antiretroviral medication also reduces the effectiveness of other drugs within the same class. However, resistance does not always affect every medication equally. Some drugs retain activity against viral strains carrying mutations associated with resistance to related medications.
Several factors influence the development and interpretation of HIV resistance:
Treatment interruptions: Repeated interruptions can allow viral replication and contribute to resistance development.
Medication adherence: Inconsistent medication use may create conditions that favor the selection of resistant viral variants.
Previous treatment exposure: Earlier antiretroviral regimens can influence which mutations are present in the virus.
Viral replication: Ongoing replication during partially effective treatment can increase opportunities for resistance mutations to emerge.
Genetic combinations: Multiple mutations may produce greater resistance than individual mutations alone.
Drug characteristics: Different medications have different genetic barriers to resistance, influencing how easily resistance develops.
Genotypic resistance testing identifies mutations in viral genetic material, particularly in the reverse transcriptase, protease, and integrase genes. Phenotypic testing evaluates how effectively medications inhibit viral replication in laboratory conditions.
Healthcare professionals interpret these findings alongside viral load measurements, treatment history, and clinical information. Resistance testing is particularly important when treatment failure is suspected or when selecting an appropriate regimen after previous antiretroviral exposure.
Understanding the relationship between individual mutations, cross-resistance, and medication activity provides an important foundation for interpreting HIV resistance patterns across drug classes.